Clinical trial
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral…
NCT00135408 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00135408 |
|---|---|
| Title | A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide |
| Official title | Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide (Entocort EC) in Patients With Previously Treated Unresectable Stage III or IV Malignant Melanoma |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Medarex Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | Ipilimumab+ Placebo, Ipilimumab+ Budesonide |
| Enrollment | 115 |
| Start date | Dec 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Aug 26, 2005 |
| Last update posted | Sep 28, 2016 |
| Countries | Canada, Israel, Italy, Peru, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: